poisar

Stock

GSK plc American Depositary Shares (Each representing two Ordinary Shares) GSK

$51.35+1.20%

Overview

GSK market data

Price History

GSK price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
13.13
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$1.39
Diluted earnings per share over the trailing twelve months.
Beta
1.21
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
367.4%
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1,361.00 – $2,282.00
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $76.5K · P/B 4.51 · P/S 2.33.

Company news

10 captured
GSK Canada Receives Approval For Shingrix Zoster Vaccine In Prefilled SyringeBenzinga · Jul 24, 2026, 3:30 PM
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of ScheduleBenzinga · Jul 22, 2026, 5:39 PM
GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung CancerBenzinga · Jul 22, 2026, 4:41 PM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease TherapiesGlobenewswire Inc · Jul 20, 2026, 4:15 PM
GSK shares are trading lower after the company announced that it will cease further development of Camlipixant as a chronic cough treatment due to its failure to meet statistical significance in two clinical trials.Benzinga · Jul 17, 2026, 5:29 PM
Disappointing Data Prompts GSK to Drop Cough Drug DevelopmentBenzinga · Jul 17, 2026, 2:48 PM
GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical TrialsBenzinga · Jul 17, 2026, 11:44 AM
American Kidney Fund Expands Kidney Health Coach Program with Educational Course on Lupus NephritisGlobenewswire Inc · Jul 16, 2026, 3:15 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock